PT  - JOURNAL ARTICLE
AU  - JARZĄB, AGATA
AU  - ŁUSZCZKI, JAROGNIEW
AU  - GUZ, MAŁGORZATA
AU  - SKALICKA-WOŹNIAK, KRYSTYNA
AU  - HAŁASA, MARTA
AU  - SMOK-KALWAT, JOLANTA
AU  - POLBERG, KRZYSZTOF
AU  - STEPULAK, ANDRZEJ
TI  - Combination of Osthole and Cisplatin Against Rhabdomyosarcoma TE671 Cells Yielded Additive Pharmacologic Interaction by Means of Isobolographic Analysis
DP  - 2018 Jan 01
TA  - Anticancer Research
PG  - 205--210
VI  - 38
IP  - 1
4099  - http://ar.iiarjournals.org/content/38/1/205.short
4100  - http://ar.iiarjournals.org/content/38/1/205.full
SO  - Anticancer Res2018 Jan 01; 38
AB  - Background/Aim: Osthole is a simple coumarin that has been found to have anticancer, anti-inflammatory, antiviral, anticoagulant, anticonvulsant and antiallergic activities. The aim of this study was to analyze the combined anti-proliferative effect of cisplatin (CDDP) and osthole on a rhabdomyosarcoma cell line, and assess the pharmacology of drug-drug interaction between these drugs using isobolographic analysis. Materials and Methods: The anticancer actions of osthole in combination with CDDP were evaluated using the tetrazolium dye-based MTT cell proliferation assay. Results: Osthole and CDDP applied together augmented their anti-cancer activities and yielded an additive type of pharmacologic interaction by means of isobolographic analysis. Conclusion: Combined therapy using osthole and cisplatin could be suggested as a potential chemotherapy regimen against rhabdomyosarcoma.